Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Agnieszka Marczak; Marta Denel

doi:10.5114/wo.2014.43153

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2014
vol. 18

Send email

Copy url:

abstract:

Review paper

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Agnieszka Marczak

,

Marta Denel

Contemp Oncol (Pozn) 2014; 18 (3): 149–152

DOI: https://doi.org/10.5114/wo.2014.43153

Online publish date: 2014/06/18

View full text Get citation

PlumX metrics:

Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.

keywords:

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Agnieszka Marczak , Marta Denel

trabectedin, chemotherapy, pegylated liposomal doxorubicin, ovarian cancer

Agnieszka Marczak

,

Marta Denel